Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 596 clinical trials
None
CAR-37 T Cells In Hematologic Malignancies

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the

tumor cells
chemotherapy regimen
mantle cell lymphoma
marginal zone lymphoma
platelet count
  • 0 views
  • 09 Nov, 2021
None
Haploidentical Donor vs mMUD in Hematological Malignancies

The goal of this trial is to compare the outcome after partially matched (single mismatch) unrelated donor transplantation with haploidentical transplantation in a randomized controlled setting.

minimal residual disease
salvage therapy
neoadjuvant therapy
induction therapy
cancer
  • 11 views
  • 03 Sep, 2021
  • 11 locations
None
FT516 in Subjects With Advanced Hematologic Malignancies

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-sepcific cohorts.

refractory acute myeloid leukemia (aml)
antibody therapy
neoadjuvant therapy
cyclophosphamide
rituximab
  • 6 views
  • 12 Mar, 2021
  • 5 locations
None
FT538 in Subjects With Advanced Hematologic Malignancies

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

refractory acute myeloid leukemia (aml)
leukemia
measurable disease
fludarabine
  • 0 views
  • 10 Oct, 2021
  • 7 locations
None
Reduced Intensity Partially HLA Mismatched BMT to Treat Hematologic Malignancies

If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the …

chronic myelomonocytic leukemia
acute leukemia
sirolimus
mantle cell lymphoma
remission
  • 17 views
  • 01 Feb, 2021
  • 1 location
None
A Study of TQB3820 in Patients With Hematological Malignancies

TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects …

measurable disease
multiple myeloma
  • 0 views
  • 27 Sep, 2021
  • 2 locations
None
A Study of GFH009 in Patients With Hematologic Malignancies

of GFH009 in relapsed/refractory hematologic malignancies [acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma], will also explore the

chronic lymphocytic leukemia
leukemia
gilbert's syndrome
lymphoma
direct bilirubin
  • 0 views
  • 23 May, 2021
  • 1 location
None
Peg Interferon -2b for Relapsed Hematological Malignancies After Allo-HSCT

Aim: to observe the graft versus tumor effect of Pegylated Interferon-2b in patients with hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT

acute graft versus host disease
blood disorder
cell transplantation
cancer
graft versus host disease
  • 8 views
  • 21 Oct, 2021
  • 1 location
None
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.

chronic myelomonocytic leukemia
antibody therapy
raeb ii
cell transplantation
myelomonocytic leukemia
  • 17 views
  • 15 Oct, 2021
  • 1 location
None
Combination CAR-T Cell Therapy Targeting Hematological Malignancies

The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral …

  • 0 views
  • 23 Jan, 2021
  • 3 locations